Key facts
- Labviva’s last known valuation is $125.0M (Dec 2024).
- It has raised $55.1M across 2 recorded rounds; the latest was Early Stage VC ($8.0M) in Jun 2021.
- Notable investors include Village Global, B Capital Group, MassVentures, SeedFolio, Glasswing Ventures — 10 tracked in total.
- Labviva has filed 2 Form Ds with the SEC since 2019, most recently Jun 2021 ($8.0M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Labviva
Funding rounds
2 roundsAbout Labviva
Developer of an AI-powered digital marketplace designed to offer visibility into life science supply chains. The company's application works with the existing procurement software and gives insights into everything from lab purchasing trends to supply chain health, enabling clients to preserve their contract pricing with preferred vendors, eliminate the need for third-party fulfillment, and add new direct partnerships without having to maintain separate catalogs.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2017
- Employees
- 75
- Website
- labviva.com/
- Ownership
- Privately Held (backing)
Labviva doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Labviva shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Labviva in its N-PORT filings yet. We sweep new filings monthly.